Sana Biotechnology has filed a patent for a method of treating virus infections, including coronavirus, by delivering a binding agent to a patient. The binding agent consists of a binding domain that attaches to a viral protein on the virus’s surface and a modified Fc domain that reduces pro-inflammatory activity. The agent can be delivered as a polynucleotide or protein, using a viral or non-viral vector. The patent also covers the composition of the binding agent and its use in the treatment method. GlobalData’s report on Sana Biotechnology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sana Biotechnology, viral vectors was a key innovation area identified from patents. Sana Biotechnology's grant share as of September 2023 was 2%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230303665A1) describes a binding agent that can neutralize viruses and reduce pro-inflammatory activity. The binding agent consists of at least one binding domain that attaches to a viral protein on the surface of the virus, and a modified Fe domain. The modified Fe domain has one or more amino acid substitutions compared to the wildtype Fe domain, resulting in reduced pro-inflammatory activity.
The patent claims also mention that the Fc domain, which is part of the binding agent, can be an IgG2 or IgG4 Fc domain. Additionally, the modified Fc domain exhibits decreased binding to Fc activating receptors and increased binding to Fc inhibitory receptors compared to the wild-type Fc domain.
The binding agent can form immune complexes with decreased pro-inflammatory activity compared to immune complexes formed with a binding agent comprising the wild-type Fc domain. The patent further specifies various amino acid substitutions in the modified Fc domain that can be used to achieve these properties.
The binding agent is particularly effective against RNA viruses, including coronaviruses such as SARS-CoV-2, SARS-CoV-1, and MERS-CoV. It can also be used against other types of viruses like orthomyxoviruses (e.g., influenza viruses) and paramyxoviruses (e.g., RSV and measles virus).
The binding agent can be produced by introducing a nucleic acid molecule encoding the binding agent into a host cell and isolating or purifying the binding agent from the cell. It can be administered to individuals known or suspected of having a viral infection to form immune complexes and reduce inflammation. The binding agent can also be used to promote inhibitory immune complex function and reduce activating immune complex function.
Overall, this patent describes a binding agent with modified domains that can effectively neutralize viruses and reduce pro-inflammatory activity, making it a potential therapeutic option for viral infections.
To know more about GlobalData’s detailed insights on Sana Biotechnology, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
